ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
2007 Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Treatment of triple negative brest cancer (TNBC): current options and future perspectives.
2010 DE LAURENTIIS, Michelino; Cianniello, Daniela; Caputo, Roberta; Stanzione, Brigida; Arpino, Grazia; Cinieri, S; Lorusso, V; DE PLACIDO, Sabino
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases.
2001 Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Simona, Cammarota; DE ANGELIS, Carmine; Claudia, Pizzi; Vincenzo, Perone; Giuseppina, Tommasielli; Giovanni, Arpino; Novellino, Ettore; DE PLACIDO, Sabino
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
2005 Arpino, Grazia; D. R., Ciocca; H., Weiss; D. C., Allred; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S. K., Mohsin
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”,
2000 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; C., Carlomagno; F., Ciardiello; G., Tortora; Ar, Bianco; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. | 1.1 Articolo in rivista | 2007 | Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm | |
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Treatment of triple negative brest cancer (TNBC): current options and future perspectives. | 1.1 Articolo in rivista | 2010 | DE LAURENTIIS, Michelino; Cianniello, Daniela; Caputo, Roberta; Stanzione, Brigida; Arpino, Grazia; Cinieri, S; Lorusso, V; DE PLACIDO, Sabino | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
| SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
| A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. | 4.1 Articoli in Atti di convegno | 2001 | Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco | |
| Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Simona, Cammarota; DE ANGELIS, Carmine; Claudia, Pizzi; Vincenzo, Perone; Giuseppina, Tommasielli; Giovanni, Arpino; Novellino, Ettore; DE PLACIDO, Sabino | |
| Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; D. R., Ciocca; H., Weiss; D. C., Allred; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S. K., Mohsin | |
| Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
| A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, | 8.02 Comunicazioni a Convegni o Seminari | 2000 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; C., Carlomagno; F., Ciardiello; G., Tortora; Ar, Bianco; DE PLACIDO, Sabino |